
Omnicell (OMCL) Stock Forecast & Price Target
Omnicell (OMCL) Analyst Ratings
Bulls say
Omnicell is expected to continue experiencing strong revenue and earnings growth due to the increasingly crucial role that its automation and business analytics software plays in the healthcare industry, as demonstrated by its recent top and bottom-line beat in 1Q26. The company's introduction of the powerful Titan XT platform, as well as its recent acquisition of Surgichem IT has allowed it to expand its addressable market for its cloud-based medication management platform, OmniSphere, to an estimated $2.5 billion. The company's focus on customer satisfaction and loyalty, as evidenced by its strong customer feedback and high conversion rates from competitors, is a key factor in driving its continued success.
Bears say
Omnicell is showing signs of strong revenue growth in FY26 due to the introduction of new products like Titan XT and XTExtend, but these upgrades and new products are expected to come at a premium cost, potentially impacting the company's margin. While the company's recent stock performance may suggest positive sentiment, there are concerns about the sustainability of this growth and if the company can continue to meet market expectations. Investors should closely monitor the company's upcoming earnings report and conference call for insights into its long-term growth strategy and any potential challenges in the healthcare market.
This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.
Omnicell (OMCL) Analyst Forecast & Price Prediction
Start investing in Omnicell (OMCL)
Order type
Buy in
Order amount
Est. shares
0 shares